Immunotherapeutics

Course content

This one-year Masters course in Immunotherapeutics is an innovative and multidisciplinary postgraduate degree taught by leading academics in the field of Immunology with guest speakers from the biopharma industry.



Students will learn about the immune system in cancer, autoimmunity, infection and neurodegeneration, and how cutting-edge immunotherapies are revolutionising the treatment of life-threatening and debilitating diseases. This course also includes the study of the exciting technologies of DNA / RNA vaccines, antibody, stem cell and CAR T-cell therapies, as well as immune-checkpoint blockade.



Additionally, skills in business development, innovation, entrepreneurship and communication will be taught and bioprocessing in the National Institute for Bioprocessing, Research and Training (NIBRT) at their state-of- the-art facility.



A key component of the course is the six-month industry placement to be completed by each student in collaboration with an academic staff member.



Is This Course For Me?

The M.Sc. in Immunotherapeutics is open to scientific, medical, dentistry, veterinary, and engineering graduates who wish to obtain in-depth knowledge of Immunotherapeutics, fundamental immunology and the technologies that underpin immunotherapeutic development. This programme is particularly suitable for graduates who wish to work in high-level jobs in the Biopharma industry or continue further academic research.

The following modules are mandatory and make up the taught components of the course: Fundamental Immunology; Bioprocessing; Advanced ImmunoTechnologies; Immunotherapeutics; Computational Immunology; Research in Action; and Innovation and Drug Development.

Applicants will normally be required to hold at least upper second-class Honours degree (2.1) or higher in Medicine, Veterinary Science, Molecular Biology, Genetics, Immunology, Biochemistry or a related subject.

Closing Date: 31st July 2024

1 year full-time

Next Intake: September 2024

Career Opportunities

To date, graduates of the M.Sc. programme in Immunotherapeutics have a 100% employment rate in careers such as R&D, communications, sales, marketing and regulatory affairs. The School of Biochemistry & Immunology is at the forefront of immunological research worldwide, with Clarivate analytics describing three Trinity immunologists in the top 1% of researchers worldwide based on number of citations.



The M.Sc. in Immunotherapeutics has a strong industry and entrepreneurial focus and is designed to provide graduates with analytical, innovation, communication and teamwork skills required for a successful career in the Immunotherapeutic / Biopharma industry or further academic research.



This Masters course has been designed in collaboration with the Biopharma industry in Ireland. Industry partners who provide to teaching and project placements include Merk Sharp & Dohme, Bristol Myers Squib, Alexion Pharmaceuticals, Takeda Pharmaceuticals, fusion antibodies, Avectas, Inflection Biosciences, Seroba Life Sciences, Carrick Therapeutics, Pfizer, HPRA, Charles Rivers Laboratories, APC, ICON.



The world’s 10 largest biopharma companies operate in Ireland, with employment in the sector growing fivefold in the last 30 years.